Article
Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial.
EBioMedicine - 1 Sept 2020
Arellanes Isabella C, Choe Nicholas, Solomon Victoria, He Xulei, Kavin Brian, Martinez Ashley E, Kono Naoko, Buennagel David P, Hazra Nalini, Kim Giselle, D'Orazio Lina M, McCleary Carol, Sagare Abhay, Zlokovic Berislav V, Hodis Howard N, Mack Wendy J, Chui Helena C, Harrington Michael G, Braskie Meredith N, Schneider Lon S, Yassine Hussein N
Abstract excerpt
BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.